Bouassiba Cosima, Mueller Ralf S
Tierärztliche Praxis Dr. Cosima Bouassiba, Birgen 10, 41366 Schwalmtal, E-Mail:
Tierarztl Prax Ausg K Kleintiere Heimtiere. 2017 Aug 10;45(4):235-244. doi: 10.15654/TPK-160234. Epub 2017 Jun 6.
Otitis externa is normally treated with daily topical medication. Longer application intervals may be useful to facilitate therapy. In this study, the in vivo efficacy of a gel preparation containing marbofloxacin, dexamethasone and enilconazole was compared to that of a commercial otologic agent containing marbofloxacin, dexamethasone and clotrimazole based on clinical signs, ear cytology and bacterial/fungal cultures.
A gel preparation (group A) or a registered otologic agent (group B), respectively, was applied to 41 dogs. A total of 50 ears (25 per group) were analysed. The gel preparation was administered on days 0 and 5; the combination preparation was administered daily according to the manufacturer's recommendations. Dogs were reevaluated clinically and cytologically after 5 and 10 days. Initially and after 10 days, ear swabs were taken for bacterial and fungal cultures.
No significant clinical or cytological differences were found between the groups. Significantly more isolates resistant to marbofloxacin were identified in group A after 10 days, although >98% of marbofloxacin was still detectable in vitro after 15 days.
The clinical and cytological efficacy of a gel containing defined active agents applied twice 5 days apart was comparable to that of an authorised otologic agent applied once daily. There appears to be an increased risk with the gel in that a resistance to fluoroquinolones develops. Local adverse effects are also possible.
A gelatine preparation containing active agents may be an alternative to daily topical therapy of canine otitis externa. The development of resistances is possible.
外耳道炎通常采用每日局部用药治疗。延长用药间隔时间可能有助于促进治疗。在本研究中,基于临床症状、耳部细胞学检查以及细菌/真菌培养,将含马波沙星、地塞米松和恩康唑的凝胶制剂的体内疗效与含马波沙星、地塞米松和克霉唑的市售耳科用药的疗效进行了比较。
分别将一种凝胶制剂(A组)或一种注册耳科用药(B组)应用于41只犬。共分析了50只耳朵(每组25只)。凝胶制剂在第0天和第5天给药;联合制剂根据制造商的建议每日给药。在第5天和第10天对犬进行临床和细胞学重新评估。在初始阶段和第10天后,采集耳部拭子进行细菌和真菌培养。
两组之间未发现显著的临床或细胞学差异。虽然15天后体外仍可检测到>98%的马波沙星,但第10天后A组中对马波沙星耐药的分离株明显更多。
间隔5天给药两次的含特定活性剂的凝胶的临床和细胞学疗效与每日给药一次的经批准耳科用药相当。凝胶似乎存在风险增加的情况,即会产生对氟喹诺酮类药物的耐药性。也可能出现局部不良反应。
含活性剂的明胶制剂可能是犬外耳道炎每日局部治疗的替代方法。可能会产生耐药性。